0001140361-16-053976.txt : 20160218
0001140361-16-053976.hdr.sgml : 20160218
20160218174557
ACCESSION NUMBER: 0001140361-16-053976
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160216
FILED AS OF DATE: 20160218
DATE AS OF CHANGE: 20160218
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 161439193
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
form4.xml
REGENERON PHARMACEUTICALS, INC FORM 4 2-16-2016 (SANOFI)
X0306
4
2016-02-16
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54 RUE LA BOETIE
PARIS
I0
75008
FRANCE
true
Common Stock
2016-02-16
4
P
0
2145
387.4283
A
23194653
I
See note
Common Stock
2016-02-16
4
P
0
2196
388.2999
A
23196849
I
See note
Common Stock
2016-02-16
4
P
0
6789
389.4759
A
23203638
I
See note
Common Stock
2016-02-16
4
P
0
14303
390.4695
A
23217941
I
See note
Common Stock
2016-02-16
4
P
0
33131
391.3591
A
23251072
I
See note
Common Stock
2016-02-16
4
P
0
14692
392.3656
A
23265764
I
See note
Common Stock
2016-02-16
4
P
0
7301
393.2723
A
23273065
I
See note
Common Stock
2016-02-16
4
P
0
600
393.95
A
23273665
I
See note
Common Stock
2016-02-17
4
P
0
1507
390.1449
A
23275172
I
See note
Common Stock
2016-02-17
4
P
0
3681
391.2307
A
23278853
I
See note
Common Stock
2016-02-17
4
P
0
27088
391.8482
A
23305941
I
See note
Common Stock
2016-02-17
4
P
0
6730
393.1577
A
23312671
I
See note
Common Stock
2016-02-17
4
P
0
12988
394.2403
A
23325659
I
See note
Common Stock
2016-02-17
4
P
0
13288
395.3203
A
23338947
I
See note
Common Stock
2016-02-17
4
P
0
11018
396.2026
A
23349965
I
See note
Common Stock
2016-02-17
4
P
0
3400
397.0707
A
23353365
I
See note
Common Stock
2016-02-17
4
P
0
300
398.38
A
23353665
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $386.74 to $387.60 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,554,113 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $387.82 to $388.73 per share, inclusive.
Purchase prices range from $388.91 to $389.90 per share, inclusive.
Purchase prices range from $389.95 to $390.93 per share, inclusive.
Purchase prices range from $390.95 to $391.93 per share, inclusive.
Purchase prices range from $391.95 to $392.94 per share, inclusive.
Purchase prices range from $392.95 to $393.87 per share, inclusive.
Purchase price was $393.95 per share.
Purchase prices range from $389.68 to $390.52 per share, inclusive.
Purchase prices range from $390.70 to $391.69 per share, inclusive.
Purchase prices range from $391.73 to $392.71 per share, inclusive.
Purchase prices range from $392.73 to $393.66 per share, inclusive.
Purchase prices range from $393.74 to $394.72 per share, inclusive.
Purchase prices range from $394.74 to $395.73 per share, inclusive.
Purchase prices range from $395.75 to $396.74 per share, inclusive.
Purchase prices range from $396.81 to $397.68 per share, inclusive.
Purchase price was $398.38 per share.
/s/ Alexandra Roger, Head of Securities Law and Capital Markets
2016-02-18